The revised Policy remains substantively the same as the previous version.
Clarifications to the Policy have been made to reflect the inclusion of ‘Medical Technologies and Pharmaceuticals’ as an Industrial Transformation Priority under the Industrial Transformation Research Program (ITRP). A number of other modifications were also made to clarify research that is eligible/ineligible for ARC support.
No. Each application submitted to the ARC is assessed for eligibility under the relevant scheme grant guidelines including where the ARC Medical Research Policy applies under the relevant scheme grant guidelines.
Yes. Each application submitted to the ARC is assessed for eligibility under the relevant scheme grant guidelines including where the ARC Medical Research Policy applies under the relevant scheme grant guidelines.
There is nothing to prevent you from doing this. The parallel application would need to be disclosed in the relevant section of the ARC application form. If both applications are successful, only one grant offer can be accepted for funding (to avoid duplication of Commonwealth funding). Note that the ARC would see a parallel bid to the NHMRC as evidence of a potential significant health and medical focus which may render it ineligible for ARC funding
Yes. Applications must take the ARC Medical Research Policy into consideration and the predominant use of the proposed infrastructure, equipment and/or facilities must not be in breach of the Policy. While there may be some incidental use of the infrastructure, equipment and/or facilities in other research areas, this cannot be the focus of the application and the main aim of the research to be supported must not be to understand the causes, treatment and/or prevention of human diseases and/or the maintenance of human health.
Yes, with regard to the ARC Medical Research Policy, but all other eligibility requirements must also be met as per the relevant scheme grant guidelines.
Yes, with regard to the ARC Medical Research Policy, but all other eligibility requirements must also be met as per the relevant scheme grant guidelines.
Yes. Applications must take the ARC Medical Research Policy into consideration and the main aim of the research to be supported must not be to understand the causes, treatment and/or prevention of human diseases and/or the maintenance of human health.
Yes. For the purposes of the ARC Medical Research Policy, the definition of medical and health research includes laboratory-based studies, clinical studies and group/community-based studies that aim to understand the causes, treatment and/or prevention of human diseases and/or the maintenance of human health. The ARC does not normally fund research with these aims.
Yes, provided the goals are not on the understanding, aetiology, diagnosis, monitoring, management or treatment of physical or mental disease or other medical and/or human health conditions.
Yes, provided the goals are not on the understanding, aetiology, diagnosis, monitoring, management or treatment of physical or mental disease or other medical and/or human health conditions.
Yes, provided the goals are not on the understanding, aetiology, diagnosis, monitoring, management or treatment of physical or mental disease or other medical and/or human health conditions.
Yes. Applications must take the ARC Medical Research Policy into consideration and the main aim of the research to be supported must not be to understand the causes, treatment and/or prevention of human diseases and/or the maintenance of human health.
Yes, provided the goals are not on the understanding, aetiology, diagnosis, monitoring, management or treatment of physical or mental disease or other medical and/or human health conditions.
The application may still be submitted, provided it clearly addresses the objectives of the Industrial Transformation Research Program. The main aim of the application must not be to understand the causes, treatment and/or prevention of human diseases and/or the maintenance of human health. The ARC will not consider any application that utilises ARC funds for clinical trials.
